MAP3K14 and plasma cell myeloma: Several predictions and experimental approaches have defined a novel miR-31 target gene, MAP3K14 (also called NIK), which is a persistent NF-κB activator in various malignancies, including B cell lymphoma (Pham et al., 2011), multiple myeloma (Annunziata et al., 2007), breast cancer (Yamamoto et al., 2010), pancreatic cancer (Nishina et al., 2009), and ATL (Saitoh et al., 2008).